Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.

Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Corea y enfermedad de Huntington Chorea & Huntington’s disease 104 artículos Viendo del 1 al 40 de 104 artículos
Pub MED

Anosognosia Is Associated With Greater Caregiver Burden and Poorer Executive Function in Huntington Disease.NUEVO

Wibawa P, Zombor R, Dragovic M, Hayhow B, Lee J, Panegyres PK, Rock D, Starkstein SE.
J Geriatr Psychiatry Neurol. 2019 Jun 18:891988719856697. doi: 10.1177/0891988719856697. [Epub ahead of print]
Pub MED

Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.NUEVO

Yu-Taeger L, Stricker-Shaver J, Arnold K, Bambynek-Dziuk P, Novati A, Singer E, Lourhmati A, Fabian C, Magg J, Riess O, Schwab M, Stolzing A, Danielyan L, Nguyen HHP.
Cells. 2019 Jun 15;8(6). pii: E595. doi: 10.3390/cells8060595.
Pub MED

Bilateral Chorea Associated with Acute Caudate Nucleus Infarctions.NUEVO

Qu Y, Jin H, Guo ZN, Zhang FL, Liu J, Qin HQ, Yang Y.
Can J Neurol Sci. 2019 Jun 14:1-2. doi: 10.1017/cjn.2019.50. [Epub ahead of print] No abstract available.
Pub MED

Novel pathogenic VPS13A gene mutations in Japanese patients with chorea-acanthocytosis.NUEVO

Nishida Y, Nakamura M, Urata Y, Kasamo K, Hiwatashi H, Yokoyama I, Mizobuchi M, Sakurai K, Osaki Y, Morita Y, Watanabe M, Yoshida K, Yamane K, Miyakoshi N, Okiyama R, Ueda T, Wakasugi N, Saitoh Y, Sakamoto T, Takahashi Y, Shibano K, Tokuoka H, et al.
Neurol Genet. 2019 May 1;5(3):e332. doi: 10.1212/NXG.0000000000000332. eCollection 2019 Jun.
Pub MED

End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.NUEVO

Carlozzi NE, Boileau NR, Paulsen JS, Perlmutter JS, Lai JS, Hahn EA, McCormack MK, Nance MA, Cella D, Barton SK, Downing NR.
J Neurol. 2019 Jun 12. doi: 10.1007/s00415-019-09417-7. [Epub ahead of print]
Pub MED

Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.NUEVO

Sanchis A, García-Gimeno MA, Cañada-Martínez AJ, Sequedo MD, Millán JM, Sanz P, Vázquez-Manrique RP.
Exp Mol Med. 2019 Jun 5;51(6):65. doi: 10.1038/s12276-019-0264-9.
Pub MED

HTT haplogroups in Finnish patients with Huntington disease.NUEVO

Ylönen S, Sipilä JOT, Hietala M, Majamaa K.
Neurol Genet. 2019 Apr 22;5(3):e334. doi: 10.1212/NXG.0000000000000334. eCollection 2019 Jun.
Pub MED

AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.NUEVO

Spronck EA, Brouwers CC, Vallès A, de Haan M, Petry H, van Deventer SJ, Konstantinova P, Evers MM.
Mol Ther Methods Clin Dev. 2019 Mar 16;13:334-343. doi: 10.1016/j.omtm.2019.03.002. eCollection 2019 Jun 14.
Pub MED

Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.NUEVO

Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA.
Mol Neurobiol. 2019 Jun;56(6):4464-4478. doi: 10.1007/s12035-018-1393-1. Epub 2018 Oct 17.
Pub MED

18F-FDG PET/CT: an unexpected case of Huntington's disease.NUEVO

Michels S, Buchholz HG, Rosar F, Heinrich I, Hoffmann MA, Schweiger S, Tüscher O, Schreckenberger M.
BMC Neurol. 2019 May 1;19(1):78. doi: 10.1186/s12883-019-1311-9.
Pub MED

Hdac4 interactions in Huntington's Disease viewed through the prism of multiomics.NUEVO

Federspiel JD, Greco TM, Lum KK, Cristea IM.
Mol Cell Proteomics. 2019 Apr 30. pii: mcp.RA118.001253. doi: 10.1074/mcp.RA118.001253. [Epub ahead of print]
Pub MED

Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.NUEVO

Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, Hayden MR, Pouladi MA.
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9622-9627. doi: 10.1073/pnas.1818042116. Epub 2019 Apr 23.
Pub MED

Clinical manifestations of homozygote allele carriers in Huntington disease.NUEVO

Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, Muñoz I, Llano K, Mariscal N, Diaz D, Gutierrez A, Aguado L, Ramos-Arroyo MA; European HD Network..
Neurology. 2019 Apr 30;92(18):e2101-e2108. doi: 10.1212/WNL.0000000000007147. Epub 2019 Mar 13.
Pub MED

Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington's Disease.NUEVO

Misiura MB, Ciarochi J, Vaidya J, Bockholt J, Johnson HJ, Calhoun VD, Paulsen JS, Turner JA; PREDICT-HD Investigators & Working Group..
J Int Neuropsychol Soc. 2019 May;25(5):462-469. doi: 10.1017/S1355617719000067. Epub 2019 Feb 26.
Pub MED

Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease.NUEVO

Osborne-Crowley K, Andrews SC, Labuschagne I, Nair A, Scahill R, Craufurd D, Tabrizi SJ, Stout JC; TRACK-HD Investigators..
J Int Neuropsychol Soc. 2019 May;25(5):453-461. doi: 10.1017/S1355617718001224. Epub 2019 Feb 15.
Pub MED

Enhanced striatopallidal gamma-aminobutyric acid (GABA)(A) receptor transmission in mouse models of huntington's disease.NUEVO

Perez-Rosello T, Gelman S, Tombaugh G, Cachope R, Beaumont V, Surmeier DJ.
Mov Disord. 2019 May;34(5):684-696. doi: 10.1002/mds.27622. Epub 2019 Feb 6.
Pub MED

Induced pluripotent stem cells from Huntington's disease patients: a promising approach to define and correct disease-related alterations.NUEVO

Fatima A, Gutiérrez-Garcia R, Vilchez D.
Neural Regen Res. 2019 May;14(5):769-770. doi: 10.4103/1673-5374.249223. No abstract available.
Pub MED

Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.NUEVO

Sampedro F, Martínez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, Camacho V, Fernández-León A, Gomez-Anson B, Carrió I, Kulisevsky J.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1111-1116. doi: 10.1007/s00259-018-4257-z. Epub 2019 Jan 9.
Pub MED

Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington's Disease Mice.NUEVO

Holley SM, Galvan L, Kamdjou T, Dong A, Levine MS, Cepeda C.
Front Synaptic Neurosci. 2019 May 14;11:14. doi: 10.3389/fnsyn.2019.00014. eCollection 2019.
Pub MED

The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: Two meta-analyses.NUEVO

Ghielen I, Rutten S, Boeschoten RE, Houniet-de Gier M, van Wegen EEH, van den Heuvel OA, Cuijpers P.
J Psychosom Res. 2019 Jul;122:43-51. doi: 10.1016/j.jpsychores.2019.05.001. Epub 2019 May 13. Review.
Pub MED

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?NUEVO

Migliore S, Jankovic J, Squitieri F.
Front Neurol. 2019 Apr 30;10:453. doi: 10.3389/fneur.2019.00453. eCollection 2019.
Pub MED

Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.NUEVO

Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, Scherer SW, Eberle MA, Yuen RKC, Hayden MR.
Am J Hum Genet. 2019 May 8. pii: S0002-9297(19)30153-3. doi: 10.1016/j.ajhg.2019.04.007. [Epub ahead of print]
Pub MED

EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.NUEVO

Marottoli FM, Priego M, Flores-Barrera E, Pisharody R, Zaldua S, Fan KD, Ekkurthi GK, Brady ST, Morfini GA, Tseng KY, Tai LM.
Mol Neurobiol. 2019 May 19. doi: 10.1007/s12035-019-1634-y. [Epub ahead of print]
Pub MED

Physical ACtivity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease.NUEVO

Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M.
Phys Ther. 2019 May 17. pii: pzz075. doi: 10.1093/ptj/pzz075. [Epub ahead of print]
Pub MED

Alterations in Synaptic Function and Plasticity in Huntington Disease.NUEVO

Smith-Dijak AI, Sepers MD, Raymond LA.
J Neurochem. 2019 May 16. doi: 10.1111/jnc.14723. [Epub ahead of print] Review.
Pub MED

The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study.NUEVO

Anderson KE, Eberly S, Marder KS, Oakes D, Kayson E, Young A, Shoulson I; PHAROS Investigators..
Clin Genet. 2019 May 15. doi: 10.1111/cge.13529. [Epub ahead of print]
Pub MED

IKKβ slows Huntington's disease progression in R6/1 mice.NUEVO

Ochaba J, Fote G, Kachemov M, Thein S, Yeung SY, Lau AL, Hernandez S, Lim RG, Casale M, Neel MJ, Monuki ES, Reidling J, Housman DE, Thompson LM, Steffan JS.
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10952-10961. doi: 10.1073/pnas.1814246116. Epub 2019 May 14.
Pub MED

Targeting the neuronal calcium sensor DREAM with small-molecules for Huntington's disease treatment.NUEVO

Lopez-Hurtado A, Peraza DA, Cercos P, Lagartera L, Gonzalez P, Dopazo XM, Herranz R, Gonzalez T, Martin-Martinez M, Mellström B, Naranjo JR, Valenzuela C, Gutierrez-Rodriguez M.
Sci Rep. 2019 May 13;9(1):7260. doi: 10.1038/s41598-019-43677-7.
Pub MED

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment.NUEVO

Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP.
Sci Rep. 2019 May 10;9(1):7202. doi: 10.1038/s41598-019-43627-3.
Pub MED

Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion.NUEVO

Sharma M, Subramaniam S.
J Cell Biol. 2019 May 10. pii: jcb.201807068. doi: 10.1083/jcb.201807068. [Epub ahead of print]
Pub MED

Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs).NUEVO

Khan E, Biswas S, Mishra SK, Mishra R, Samanta S, Mishra A, Tawani A, Kumar A.
Biochimie. 2019 May 8;163:21-32. doi: 10.1016/j.biochi.2019.05.001. [Epub ahead of print]
Pub MED

PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.NUEVO

Lloret A, Beal MF.
Neurochem Res. 2019 May 7. doi: 10.1007/s11064-019-02809-1. [Epub ahead of print]
Pub MED

Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.NUEVO

Vezzoli E, Caron I, Talpo F, Besusso D, Conforti P, Battaglia E, Sogne E, Falqui A, Petricca L, Verani M, Martufi P, Caricasole A, Bresciani A, Cecchetti O, Rivetti di Val Cervo P, Sancini G, Riess O, Nguyen H, Seipold L, Saftig P, Biella G, Cattaneo E, et al.
J Clin Invest. 2019 May 6;130. pii: 120616. doi: 10.1172/JCI120616. eCollection 2019 May 6.
Pub MED

New Intrusion Analyses on the CVLT-3: Utility in Distinguishing the Memory Disorders of Alzheimer's versus Huntington's Disease.NUEVO

Graves LV, Holden HM, Van Etten EJ, Delano-Wood L, Bondi MW, Salmon DP, Corey-Bloom J, Gilbert PE, Delis DC.
J Int Neuropsychol Soc. 2019 May 7:1-6. doi: 10.1017/S1355617719000407. [Epub ahead of print]
Pub MED

Targeting Huntingtin Expression in Patients with Huntington's Disease.NUEVO

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM.
N Engl J Med. 2019 May 6. doi: 10.1056/NEJMoa1900907. [Epub ahead of print]
Pub MED

Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.NUEVO

Puginier E, Bharatiya R, Chagraoui A, Manem J, Cho YH, Garret M, De Deurwaerdère P.
Neurochem Int. 2019 May 2;128:186-195. doi: 10.1016/j.neuint.2019.05.001. [Epub ahead of print]
Pub MED

Myelin Breakdown in Human Huntington's Disease: Multi-Modal Evidence from Diffusion MRI and Quantitative Magnetization Transfer.

Bourbon-Teles J, Bells S, Jones DK, Coulthard E, Rosser A, Metzler-Baddeley C.
Neuroscience. 2019 Apr 1;403:79-92. doi: 10.1016/j.neuroscience.2017.05.042. Epub 2017 Jun 1.
Pub MED

Cortical circuit alterations precede motor impairments in Huntington's disease mice.

Burgold J, Schulz-Trieglaff EK, Voelkl K, Gutiérrez-Ángel S, Bader JM, Hosp F, Mann M, Arzberger T, Klein R, Liebscher S, Dudanova I.
Sci Rep. 2019 Apr 29;9(1):6634. doi: 10.1038/s41598-019-43024-w.
Pub MED

Biological Motion Perception in Huntington's Disease.

Matheis T, Evinger C, Schubert R, Mazzola S, Fels M, Kemper N, Reilmann R, Muratori L.
J Huntingtons Dis. 2019 Apr 22. doi: 10.3233/JHD-180337. [Epub ahead of print]
Pub MED

Sleep Disorders in Huntington's Disease.

Herzog-Krzywoszanska R, Krzywoszanski L.
Front Psychiatry. 2019 Apr 12;10:221. doi: 10.3389/fpsyt.2019.00221. eCollection 2019. Review.
Viendo del 1 al 40 de 104 artículos
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy